ALSO NOTED: Bayer inks $344M deal for Possis; Indian drug makers not hungry for deals;

> Bayer's Medrad unit has agreed to pay about $344 million for Possis Medical, a 36 percent premium over the company's closing stock price on Friday. Report

> Indian pharma companies are shy of making any overseas acquisitions in 2008 as they continue to work through big-ticket takeovers made in 2006, market observers say. Report

> Hospital meds company Maelor is launching Aloxi, a new generation anti-emetic for use in chemo patients, in the U.K. Report

> India's Biocon is buying a 70 percent stake in the German pharma AxiCorp. Report

> In another display of monoclonal antibodies' appeal to drug developers, Maryland-based Humab Genome Sciences announced that it will team up with Xencor on drug development. Report

> According to public records, Millennium Pharmaceuticals spent $1.3 million in 2007 lobbying the federal government on patent reform and biotech drug regulation. Report

> Memory Pharmaceuticals' CEO Jim Sulat has announced plans to step down from the position for personal reasons. Report

> RNAi trailblazer Alnylam has published a paper in the journal Human Molecular Genetics that details RNAi's ability to silence a gene implicated in early onset torsion dystonia. Report

And Finally... We'd be healthier if we all got a little medieval on our diets. Report

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.